Ravi Gangal
AZB & Partners
Articles
Snapshot: anticompetitive unilateral conduct in the pharmaceutical sector in India
India - June 30 2020 A look at key practical considerations surrounding abuse of dominance and other anticompetitive unilateral conduct in the pharmaceutical sector in India, including IP rights abuse and pricing conduct.
Aditi Gopalakrishnan, Nripi Jolly, Pranav Mody, Rahul Satyan.
At a glance: pharmaceutical merger review in India
India - June 30 2020 This article looks at some of the key legal and practical issues surrounding the competition authorities' review of mergers in the pharmaceutical sector in India, including review triggers and thresholds.
Aditi Gopalakrishnan, Nripi Jolly, Pranav Mody, Rahul Satyan.
In brief: anticompetitive agreements in the pharmaceutical sector in India
India - June 30 2020 The essential legal considerations surrounding anticompetitive agreements in the pharmaceutical sector in India, including the assessment framework and special issues with vertical agreements.
Aditi Gopalakrishnan, Nripi Jolly, Pranav Mody, Rahul Satyan.
Anticompetitive agreements in the pharmaceutical sector in India
India - September 6 2019 An overview of essential considerations surrounding anticompetitive agreements in the pharmaceutical sector in India, including the assessment framework and special issues with vertical agreements.
Aditi Gopalakrishnan, Nripi Jolly, Pranav Mody, Rahul Satyan.
Pharmaceutical antitrust law in India
India - September 6 2019 A structured guide to antitrust law in the pharmaceutical sector in India, including the legislative and regulatory framework, merger review, anticompetitive agreements and abuse of dominance.
Aditi Gopalakrishnan, Nripi Jolly, Pranav Mody, Rahul Satyan.
